NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,413.79 +206.66 (+1.14%) CRUDE OIL
79.21 +0.26 (+0.33%) GOLD FUTURES
2,314.50 +4.90 (+0.21%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,466.26 +1,700.86 (+3.72%)
MRK Jan 2025 145.000 call
| Previous close | 3.4000 |
| Open | 3.4000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 145.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.3500 - 3.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
BenzingaMerck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in fighting melanoma. Merck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockb
Insider Monkey15 Best Places to Retire in Florida That You’ve Never Heard Of
This article takes a look at the 15 best places to retire in Florida that you’ve never heard of. If you wish to skip our detailed analysis of financial challenges and hidden gems in Florida, you may go to the 5 Best Places to Retire in Florida That You’ve Never Heard Of. Navigating Financial Challenges […]
Business WireMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
